Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -$38.5 million.

  • Legend Biotech's Income from Continuing Operations rose 66.98% to -$38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$243.1 million, marking a year-over-year increase of 28.30%. This contributed to the annual value of -$177.0 million for FY2024, which is 65.84% up from last year.
  • Legend Biotech's Income from Continuing Operations amounted to -$38.5 million in Q3 2025, which was up 69.04% from -$124.2 million recorded in Q2 2025.
  • Legend Biotech's Income from Continuing Operations' 5-year high stood at $335.7 million during Q4 2022, with a 5-year trough of -$557.1 million in Q3 2022.
  • Its 3-year average for Income from Continuing Operations is -$86.8 million, with a median of -$97.3 million in 2025.
  • The largest annual percentage gain for Legend Biotech's Income from Continuing Operations in the last 5 years was 496.19% (2022), contrasted with its biggest fall of 32,288.91% (2022).
  • Legend Biotech's Income from Continuing Operations (Quarterly) stood at -$84.7 million in 2021, then surged by 496.19% to $335.7 million in 2022, then plummeted by 143.21% to -$145.0 million in 2023, then soared by 111.68% to $16.9 million in 2024, then skyrocketed by 66.98% to -$38.5 million in 2025.
  • Its Income from Continuing Operations stands at -$38.5 million for Q3 2025, versus -$124.2 million for Q2 2025 and -$97.3 million for Q1 2025.